http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107739410-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 |
| filingDate | 2017-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107739410-B |
| titleOfInvention | CD3 single-chain antibody-iRGD fusion protein, preparation and application thereof as antitumor drug |
| abstract | The invention discloses a CD3 single-chain antibody-iRGD fusion protein, preparation and application thereof as an anti-tumor medicament. The invention takes the penetrating peptide iRGD component as a molecule for realizing the active targeting and high penetrability of the tumor, and connects the single-chain antibody of CD3 with the penetrating peptide iRGD component to form a fusion protein which can activate T cells and effectively target and kill tumor cells. Repeated experiments after successful construction prove that the invention has definite tumor targeting property and high penetrability, can practically enhance the anti-tumor treatment effect of immune cells, and is applied to anti-tumor drugs. |
| priorityDate | 2017-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 209.